Dalfampridine

Common brands: Ampyra, Baclofen (Intrathecal), Lyvispah, Lioresal (Baclofen), Baclofen

Top reporter: Merz Pharmaceuticals, Llc

Potassium Channel Blocker [EPC]gamma-Aminobutyric Acid-ergic Agonist [EPC]Provitamin D2 Compound [EPC]Nonsteroidal Anti-inflammatory Drug [EPC]Interferon beta [EPC]
71,175
Total Reports
9,440
Serious Reports
1,751
Death Reports
30
Reported Reactions
Death Report Ratio: Moderate (2.46%)

Patient Demographics

Male
17,537
Female
49,823

Reported Adverse Reactions (30)

Side effects reported in FDA adverse event reports for Dalfampridine.

# Reaction Reports % of Total
1 GAIT DISTURBANCE 10,964
10.5%
2 DRUG INEFFECTIVE 8,299
7.9%
3 FALL 7,323
7.0%
4 FATIGUE 5,511
5.3%
5 BALANCE DISORDER 4,897
4.7%
6 MULTIPLE SCLEROSIS RELAPSE 4,766
4.6%
7 THERAPY CESSATION 4,510
4.3%
8 DIZZINESS 3,986
3.8%
9 URINARY TRACT INFECTION 3,734
3.6%
10 CONDITION AGGRAVATED 3,482
3.3%
11 ASTHENIA 3,456
3.3%
12 INSOMNIA 3,305
3.2%
13 HEADACHE 3,259
3.1%
14 MULTIPLE SCLEROSIS 3,117
3.0%
15 MOBILITY DECREASED 2,995
2.9%
16 NAUSEA 2,812
2.7%
17 MUSCULAR WEAKNESS 2,785
2.7%
18 MEMORY IMPAIRMENT 2,442
2.3%
19 FLUSHING 2,242
2.1%
20 PAIN 2,154
2.1%
21 DRUG DOSE OMISSION 2,151
2.1%
22 HYPOAESTHESIA 2,001
1.9%
23 DEPRESSION 1,989
1.9%
24 MALAISE 1,929
1.8%
25 BACK PAIN 1,897
1.8%
26 PAIN IN EXTREMITY 1,845
1.8%
27 PARAESTHESIA 1,803
1.7%
28 DIARRHOEA 1,676
1.6%
29 INAPPROPRIATE SCHEDULE OF DRUG ADMINISTRATION 1,666
1.6%
30 MUSCLE SPASMS 1,594
1.5%

Important Disclaimer

FDA adverse event reports are submitted voluntarily and do not prove causation. A reported reaction does not mean the drug caused it. Drugs with more users naturally have more reports. Always consult your doctor or pharmacist before making medication decisions.